Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases

Part of paid clinical trials in Pittsburgh, Pennsylvania.

Sponsor
Liza Villaruz, MD
Study ID
NCT05746481
Phase
PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Tiragolumab — DRUG
    Tiragolumab (an investigational novel immune checkpoint inhibitor): 600 mg IV for induction treatment administered on Day 1 of each 21-day cycle for 4 cycles. Maintenance therapy will continue with tiragolumab on Day 1 of each 21-day cycle.
  • Atezolizumab — DRUG
    Atezolizumab (monoclonal antibody): 1200 mg IV administered on Day 1 of each 21-day cycle.
  • Pemetrexed — DRUG
    Pemetrexed (antifolate antineoplastic agent chemotherapy): 500 mg/m2 administered IV on Day 1 of each 21-day cycle.
  • Carboplatin — DRUG
    Carboplatin AUC 5 (alkylating agent chemotherapy): injection administered on Day 1 of each 21-day cycle.

Study Details

This clinical trial is aimed at the evaluation of the safety and clinical activity of tiragolumab in combination with atezolizumab with or without chemotherapy in the first line treatment of metastatic non-squamous NSCLC patients with asymptomatic untreated brain metastases.

Key Dates

Start date
Aug 10, 2023
Status verified
Jan 2026
Primary completion
Aug 19, 2024
Completion
Nov 8, 2025

Study Design

Enrollment
3 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Single Treatment Arm
    Tiragolumab in combination with atezolizumab, pemetrexed, and carboplatin.

Primary Outcome Measure

Rate of Initiation of Salvage Radiation Therapy to Central Nervous System (CNS) [ Time Frame: Up to 18 weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
UPMC Hillman Cancer CenterPittsburghPennsylvania15232-

Related coverage on Hipa.ai

Find similar trials in Pittsburgh, PA

By condition
Lung cancer
By specialty
OncologyLung oncologyLung disease
By research site
UPMC Hillman Cancer Center· Pittsburgh, PA

Related Studies